SUPN
Supernus Pharmaceuticals IncNASDAQ
Healthcare • Drug Manufacturers - Specialty & Generic
Factor tilt: Small-Cap Blend
$26.16-2.17%
Close Nov 6, 2026
- Market cap
- $1.52B
- 1 month
- -39.2%
- 3 months
- -45.1%
- 1 year
- -54.1%
- 52-week range
- $26.16$56.32
- Dividend
- No payments on record
- Short interest
- 7.8% of float4M shares · settled Oct 15, 2026 · -18.9% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Sep 30, 2026
- Revenue
- $865.11M
- Net income
- -$43.86M
- Free cash flow
- $86.96M
- Book value
- $1.06B
- Total debt
- $36.2M
- P/E
- —
- Price / sales
- —
- Price / book
- —
- FCF yield
- —
- Net margin
- -5.1%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
Read more
It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
- Website
- supernus.com
- Headquarters
- Rockville, MD, United States
- Employees
- 778
- Listed
- May 1, 2012
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 1, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2026filed Oct 29, 2026 | $226.8M | +18.0% | 88.1% | $21.2M | $20.9M |
| Jun 2026filed Aug 3, 2026 | $219.1M | +32.4% | 84.6% | -$58.0M | -$58.4M |
| Mar 2026filed May 5, 2026 | $207.7M | +38.6% | 88.7% | -$7.4M | -$2.3M |
| Dec 2025filed Mar 2, 2026 | $211.6M | +21.5% | 89.1% | $13.8M | -$4.1M |
| Sep 2025filed Nov 6, 2025 | $192.1M | +9.3% | 90.1% | -$60.2M | -$45.1M |
| Jun 2025filed Aug 5, 2025 | $165.5M | -1.7% | 89.8% | $12.1M | $22.5M |
| Mar 2025filed May 6, 2025 | $149.8M | +4.3% | 89.5% | -$10.3M | -$11.8M |
| Dec 2024filed Feb 25, 2025 | $174.2M | +6.0% | 85.0% | $21.4M | $15.3M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 2, 2026 | $719.0M | +8.6% | 89.6% | -$36.9M | -$38.6M |
| Dec 2024filed Feb 25, 2025 | $661.8M | +8.9% | 88.2% | $81.7M | $73.9M |
| Dec 2023filed Feb 27, 2024 | $607.5M | -8.9% | 86.2% | -$5.3M | $1.3M |
| Dec 2022filed Mar 9, 2023 | $667.2M | +15.1% | 86.9% | $46.1M | $60.7M |
| Dec 2021filed Apr 13, 2022 | $579.8M | +11.4% | 87.1% | $86.0M | $53.4M |
| Dec 2020filed Mar 8, 2021 | $520.4M | +32.5% | 89.9% | $173.7M | $127.0M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched SUPN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
4,043,677 shares short
-942,252 shares (-18.9%) vs Sep 30, 2026
7.8% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
4,985,929 shares short
-3,492 shares (-0.1%) vs Sep 15, 2026
9.6% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,989,421 shares short
+317,561 shares (+6.8%) vs Aug 31, 2026
9.6% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
4,671,860 shares short
+524,231 shares (+12.6%) vs Aug 14, 2026
9% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
4,147,629 shares short
-669,294 shares (-13.9%) vs Jul 31, 2026
8% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,816,923 shares short
-33,938 shares (-0.7%) vs Jul 15, 2026
9.2% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind SUPN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
USD 8.13 per share
Ex-dividend date: Nov 3, 2026
Recorded pay date: Nov 6, 2026 (past date)
Special cash dividend · Polygon event record
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if SUPN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
35 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 27, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
333 filers reported a long position in SUPN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
52.6%
of the 60.2M shares 13-F filers reported
Moves vs Q1 2026
8 added2 trimmed
Net shares held
+7.9%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $434.9M · 9.4M shares | 9.4M | +6.3% |
| 2 | MILLENNIUM MANAGEMENT LLC | $179.2M · 3.9M shares | 3.9M | +16.2% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | $153.7M · 3.3M shares | 3.3M | +2.1% |
| 4 | ARMISTICE CAPITAL, LLC | $123.1M · 2.6M shares | 2.6M | +39.6% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $117.1M · 2.5M shares | 2.5M | +2% |
| 6 | STATE STREET CORP | $114.4M · 2.5M shares | 2.5M | +7.5% |
| 7 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $110.6M · 2.4M shares | 2.4M | +16.7% |
| 8 | DIMENSIONAL FUND ADVISORS LP | $96.7M · 2.1M shares | 2.1M | -9.9% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $73M · 1.6M shares | 1.6M | -3.3% |
| 10 | Stephens Investment Management Group LLC | $69.1M · 1.5M shares | 1.5M | +10% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of SUPN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 6, 2026 | MILLENNIUM MANAGEMENT LLC13G · passive · amended | 6.6% |
| Apr 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive | 5.03% |
| Apr 29, 2026 | VANGUARD PORTFOLIO MANAGEMENT LLC13G · passive | 5.66% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for SUPN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.